Key result
The latest generation of drug-eluting stents achieves the lowest rates of restenosis, stent thrombosis, and recurrent myocardial infarction compared to bare metal stents and balloon angioplasty.
Why the study?
Do newer generation coronary artery stents improve efficacy and safety compared to older technologies in patients with coronary artery disease?
Do newer generation coronary artery stents improve efficacy and safety compared to older technologies in patients with coronary artery disease?
The latest generation of drug-eluting stents provides incremental advances over balloon angioplasty and bare metal stents, achieving lower rates of restenosis, stent thrombosis, and recurrent myocardial infarction.
Favors latest-generation DES as first-line in CAD; extends prior trial comparisons of BMS and earlier stents.
The introduction of percutaneous coronary intervention (PCI) in the late 1970s revolutionized the management of stable and unstable coronary artery disease, providing an effective, quick, safe, and increasingly widely available method for coronary revascularization for many patients. Rapid development in this field led to the introduction of a number of new technologies, including intracoronary stents that have resulted in improved efficacy and long-term safety. In this manuscript we review the experience with the 2 major available classes of stents (bare metal [BMS], drug-eluting [DES]) and describe the delivery systems for these stents. An evidence review of the large trial data comparing balloon angioplasty, BMS, and DES demonstrates the incremental advances over time, with the latest generation of DES achieving the lowest rates of restenosis, stent thrombosis, and recurrent myocardial infarction. In addition, we provide an overview of the latest developments in stent technology, including the introduction of bioresorbable stents and new stent delivery systems. These latest advances are hoped to further improve outcomes while reducing costs due to a reduction in the need for future procedures and hospitalizations due to recurrent coronary disease.
No takes yet. Share an insight, caveat, or question.
Sheth et al. (2014) conducted a review in stable and unstable coronary artery disease. Coronary Artery Stents (BMS and DES) vs. Balloon angioplasty was evaluated. The latest generation of drug-eluting stents achieves the lowest rates of restenosis, stent thrombosis, and recurrent myocardial infarction compared to bare metal stents and balloon angioplasty.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: